Opinion|Videos|October 25, 2024
CROWN and BRIGHTSTAR Studies: Latest Data Insights
Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
Advertisement
- Dr Bestvina: Please discuss the key findings from the latest data for the CROWN/BRIGHTSTAR studies.
- CROWN
- Please specifically discuss and emphasize efficacy end points here. How does the efficacy of this regimen compare with that of others in this space?
- BRIGHTSTAR
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5
































